Two Sigma Advisers
CRSP icon

Two Sigma Advisers’s CRISPR Therapeutics CRSP Stock Holding History

Two Sigma Advisers’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-162,400
Closed -$8.52M – 513
2025
Q4 		$8.52M Sell
162,400
-410,572
-72% -$24.6M 0.02% 599
2025
Q3 		$37.1M Sell
572,972
-771,728
-57% -$44.3M 0.07% 215
2025
Q2 		$65.4M Buy
1,344,700
+547,500
+69% +$21.2M 0.13% 154
2025
Q1 		$27.1M Buy
797,200
+712,400
+840% +$30.2M 0.06% 279
2024
Q4 		$3.34M Buy
84,800
+28,400
+50% +$1.34M 0.01% 884
2024
Q3 		$2.65M Buy
+56,400
New +$2.86M 0.01% 944
2023
Q4 		– Sell
-9,600
Closed -$436K – 2525
2023
Q3 		$436K Sell
9,600
-7,700
-45% -$398K ﹤0.01% 1840
2023
Q2 		$971K Buy
+17,300
New +$982K ﹤0.01% 1548
2021
Q4 		– Sell
-220,600
Closed -$24.7M – 2658
2021
Q3 		$24.7M Sell
220,600
-684,200
-76% -$85.9M 0.06% 272
2021
Q2 		$146M Sell
904,800
-122,900
-12% -$14.9M 0.39% 62
2021
Q1 		$125M Buy
1,027,700
+668,000
+186% +$101M 0.34% 64
2020
Q4 		$55.1M Buy
359,700
+37,200
+12% +$4.4M 0.15% 150
2020
Q3 		$27M Buy
322,500
+88,800
+38% +$7.88M 0.08% 246
2020
Q2 		$17.2M Buy
233,700
+6,800
+3% +$398K 0.05% 366
2020
Q1 		$9.62M Sell
226,900
-60,800
-21% -$3.14M 0.04% 492
2019
Q4 		$17.5M Buy
287,700
+230,400
+402% +$12.6M 0.04% 423
2019
Q3 		$2.35M Sell
57,300
-54,800
-49% -$2.62M 0.01% 1051
2019
Q2 		$5.28M Sell
112,100
-127,300
-53% -$5.09M 0.01% 805
2019
Q1 		$8.55M Sell
239,400
-233,700
-49% -$8.08M 0.02% 660
2018
Q4 		$13.5M Buy
473,100
+60,000
+15% +$2.09M 0.04% 482
2018
Q3 		$18.3M Buy
413,100
+44,500
+12% +$2.33M 0.04% 414
2018
Q2 		$21.7M Buy
368,600
+334,200
+972% +$19M 0.06% 374
2018
Q1 		$1.57M Buy
+34,400
New +$1.42M ﹤0.01% 1352

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Two Sigma Advisers's CRSP Position: Q1 2026 in Review

Two Sigma Advisers sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 162,400 shares — an estimated $8.52M sold.

Two Sigma Advisers first reported a position in CRSP in Q1 2018 and held it in 23 quarters. The position peaked at $146M in Q2 2021. 492 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Two Sigma Advisers reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 162,400 CRISPR Therapeutics shares in Q1 2026, an estimated $8.52M.
  • Two Sigma Advisers first reported a position in CRISPR Therapeutics in Q1 2018 and held it in 23 quarters.
  • Two Sigma Advisers's CRISPR Therapeutics position peaked at $146M in Q2 2021.
  • 492 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.